UnitedHealth Stock (UNH): Wall Street Stays Bullish While Waiting for a Turnaround

UnitedHealth (UNH) stock has plunged 40% year-to-date due to disappointing financials driven by higher Medicare Advantage medical costs and an expanding DOJ probe into its Medicare billing practices, now including Optum Rx's reimbursement policies. Despite these significant headwinds and lowered price targets, most Wall Street analysts, including Morgan Stanley and Mizuho, maintain 'Buy' ratings, anticipating a multi-year turnaround post-2026 fueled by margin improvements and execution. This long-term optimism is shared by institutional investors like Berkshire Hathaway and Appaloosa Management, who have revealed stakes, viewing the current valuation as attractive.

Analysis

UnitedHealth (UNH) is facing significant headwinds, evidenced by a 40% year-to-date stock decline driven by an expanding U.S. Department of Justice (DOJ) investigation and deteriorating financials. The DOJ probe, initially focused on Medicare billing, now reportedly includes the reimbursement practices of its Optum Rx pharmacy benefit manager, amplifying regulatory risk. Financially, the company missed Q2 earnings expectations due to elevated medical costs within its Medicare Advantage plans, a pressure that Mizuho analyst Ann Hynes expects to persist into 2026. Consequently, analysts have tempered near-term expectations, with Morgan Stanley lowering its price target to $325 and Mizuho to $300. Despite these challenges, a strong consensus among analysts (17 Buys) and prominent investors like Berkshire Hathaway and Appaloosa Management points to a long-term bullish thesis. This optimism is predicated on a multi-year turnaround story, with analysts like Morgan Stanley's Erin Wright forecasting accelerated margin improvement and a steep recovery beyond 2026, contingent on successful execution, particularly at Optum Health. The current average price target of $314.95 suggests limited near-term upside, but the steep valuation pullback is viewed as an attractive entry point by long-term investors banking on the company's scale and diversified business model.

Key Decisions for Investors

• For long-term investors with high risk tolerance, the 40% stock price decline and attractive valuation, endorsed by institutional buying from Berkshire Hathaway and Appaloosa, may present a strategic entry point for a multi-year holding period.
• Investors should closely monitor developments in the DOJ investigation and medical cost trends, as these are the primary catalysts for the stock's underperformance and are expected to create volatility and pressure financials through 2026.
• Despite the 'Strong Buy' consensus rating, the average analyst price target implies only 3.6% upside, suggesting that investors should temper expectations for a rapid rebound and be prepared for a prolonged recovery.